Advice

Following an abbreviated submission

rivastigmine transdermal patch (Exelon®) is accepted for restricted use within NHS Scotland for symptomatic treatment of moderately severe Alzheimer’s dementia only.

It should be used in accordance with guidance from NHS Quality Improvement Scotland on the application of the National Institute for Health and Clinical Excellence (NICE) technology appraisal number 111. Within this context it is suitable for patients in whom rivastigmine is an appropriate choice of acetylcholinesterase inhibitor and in whom a transdermal patch is an appropriate choice of formulation.

Download detailed advice27KB (PDF)

Download

Medicine details

Medicine name:
rivastigmine 4.6mg/24h and 9.5mg/24h transdermal Patch
SMC ID:
414/07
Indication:
Alzheimer' s dementia
Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
BNF chapter
Central nervous system
Submission type
Abbreviated
Status
Superseded
Date advice published
12 November 2007
Additional notes

NICE MTA Advice: SMC Advice is superseded by National Institute for Health and Clinical Excellence (NICE) Multiple Technology Appraisal (MTA)